SpiceWeasel
Tre Kronor
Guide for AMEs said:[h=2]Pharmaceuticals (Therapeutic Medications)
Malaria Medications[/h]
- Code of Federal Regulations
- Medical History - Mefloquine (Lariam) is associated with adverse neuropsychiatric side-effects, even weeks after the drug is discontinued. This medication is absolutely disqualifying for pilots. Because of the association with adverse neuropsychiatric side-effects, even weeks after discontinuation, a pilot who elects to use mefloquine for malaria prophylaxis or who contracts malaria and is treated with mefloquine will be disqualified for pilot duties for the duration of use of mefloquine and for 4 weeks after the last dose. In this instance, the pilot must contact the FAA or his/her Aviation Medical Examiner prior to returning to flight duties after use.
- Aeromedical Decision Considerations - See Medical History section above.
- Protocol - N/A
- Pharmaceutical Considerations - See Medical History section above.
leftseat.com ATC Medical Certification said:All currently used oral drugs for malaria prevention (e.g., mefloquine [Lariam], sulfadoxine/pyrimethamine [Fansidar], Chloroquine [Aralen]) are acceptable after a period of observation for adverse effects. Mefloquin can cause psychiatric symptoms ranging from anxiety, restlessness, confusion, paranoia and depression to hallucinations, psychotic behavior, suicidal thoughts and suicide. These symptoms have been reported even long after mefloquine has been stopped. Use of mefloquine requires awareness of and close monitoring for these potential side effects. If any occur, promptly report them to your RFS and your treating physician.
http://www.leftseat.com/atc/atcsmeds.htm
Dr. Forred,
Why is there such a difference in how the FAA treats pilots vs. Air Trafffic Controllers? I called the Pacific Regional FAA Aviation Medical Office asking about this drug and ATC, and they led me down an even more confusing path - differing standards for Contract vs. FAA towers.
Thank you.